🚀
Enjoy a 7-Day Free Trial Thru Apr 30, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
UCB SA (XBRU:UCB)
News
UCB SA
XBRU
:UCB (Belgium)
Ordinary Shares
€ 122.00
(+0.66%)
Apr 22
P/E:
69.32
P/B:
2.58
Market Cap:
€ 23.15B
($ 24.71B)
Enterprise V:
€ 25.13B
($ 26.83B)
Volume:
311.89K
Avg Vol (2M):
345.18K
Warning! GuruFocus detected 3 Severe warning signs with UCB.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
311.89K
Market Cap €:
23.15B
Market Cap $:
24.71B
PE Ratio:
69.32
Avg Vol (2M):
345.18K
Enterprise Value €:
25.13B
Enterprise Value $:
26.83B
PB Ratio:
2.58
Alerts
Website
Sources
Stock PDF
Dataset
Financial Download
Manual of Stocks™
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
UCB SA (XBRU:UCB) Stock News, Headlines & Updates
UCB SA Stock News from GuruFocus
Total 90
1
2
3
Apr 10, 2024
UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa
PRNewswire
•
8:00am
Apr 04, 2024
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations
PRNewswire
•
7:00am
Mar 09, 2024
First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
PRNewswire
•
12:00pm
Mar 08, 2024
BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count
PRNewswire
•
12:00pm
Feb 29, 2024
Full Year 2023 Ucb SA Earnings Call Transcript
GuruFocus Research
•
11:04pm
Feb 15, 2024
Half Year 2023 Ucb SA Earnings Call Transcript
GuruFocus Research
•
3:22am
Ucb SA Update on BKZ US Review and Rystiggo US Approval Call Transcript
GuruFocus Research
•
3:21am
Full Year 2022 Ucb SA Earnings Call Transcript
GuruFocus Research
•
3:21am
Full Year 2021 UCB SA Earnings Call Transcript
GuruFocus Research
•
3:21am
UCB SA to Acquire Zogenix Inc Capital Markets Call Transcript
GuruFocus Research
•
3:21am
Half Year 2021 UCB SA Earnings Call Transcript
GuruFocus Research
•
3:21am
Full Year 2020 UCB SA Earnings Call Transcript
GuruFocus Research
•
3:21am
UCB SA at JPMorgan Healthcare Conference (Virtual) Transcript
GuruFocus Research
•
3:21am
Ucb SA Analysts and Investors Conference Call Transcript
GuruFocus Research
•
3:21am
Q2 2020 Ucb SA Earnings Call Transcript
GuruFocus Research
•
3:21am
Full Year 2019 Ucb SA Earnings Call Transcript
GuruFocus Research
•
3:21am
Ucb SA to Acquire Ra Pharmaceuticals Inc Call Transcript
GuruFocus Research
•
3:21am
Q2 2019 Ucb SA Earnings Call Transcript
GuruFocus Research
•
3:21am
Q4 2018 Ucb SA Earnings Call Transcript
GuruFocus Research
•
3:21am
Jan 03, 2024
ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive
PRNewswire
•
7:00am
Dec 02, 2023
UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting
PRNewswire
•
7:00am
Dec 01, 2023
UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting
PRNewswire
•
7:00am
Nov 14, 2023
UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
PRNewswire
•
7:00am
Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)
PRNewswire
•
12:00am
UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023
PRNewswire
•
12:00am
Oct 18, 2023
BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
PRNewswire
•
7:00am
Oct 17, 2023
UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis
PRNewswire
•
6:00pm
Oct 13, 2023
UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023
PRNewswire
•
12:00pm
Oct 12, 2023
Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa
PRNewswire
•
12:00pm
Oct 04, 2023
UCB presents late-breaking posters at Child Neurology Society Meeting
PRNewswire
•
1:00pm
Jul 21, 2023
UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
PRNewswire
•
7:00am
Jun 27, 2023
UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis
PRNewswire
•
7:00am
Nov 15, 2022
Top 5 3rd Quarter Trades of WELLINGTON MANAGEMENT GROUP LLP
GuruFocus Research
•
4:00pm
Apr 23, 2021
UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021
PRNewswire
•
10:01am
"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis
PRNewswire
•
10:01am
Mar 09, 2021
Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs
PRNewswire
•
11:03am
Feb 25, 2021
UCB Full Year Report 2020: UCB - sustaining growth, now and into the future
PRNewswire
•
7:03am
Feb 23, 2021
UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development
PRNewswire
•
7:03am
Jan 13, 2021
UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy
PRNewswire
•
7:02am
Dec 04, 2020
UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society's Virtual Event AES2020
PRNewswire
•
7:01am
Total 90
1
2
3
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news